1a) to measure different types of cysteine oxidation in CSF samples from ALS patients at two time points 4 months apart (visit 1, n = 24 and visit 2, n = 15) compared to healthy controls (HCs) (visit 1, n = 20 and visit 2, n = 11) (Table S1)
Prior experience with GLP-1 medications provides some guidance but does not guarantee similar experiences with multi-receptor agonists
Food and Drug Administration formally declared the semaglutide injection shortage resolved. In the months that followed, the FDA also confirmed the resolution of tirzepatide injection shortages and clarified post-shortage compounding expectations., Despite this, online advertisements continue to promote compounded GLP-1 medications
The main reason for this difference lies in the disparity between preclinical research and clinical research, that is, the contradiction that GLP-1 receptor agonists show muscle-protective effects in animal models but are accompanied by fat-free body weight loss in humans
